Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors

NCT03997968 is registered in ClinicalTrials.gov with Cyteir Therapeutics, Inc. as lead sponsor.

NCT NCT03997968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03997968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Lead sponsor
Cyteir Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 9, 2019
Completion date
December 20, 2024
Enrollment
169 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cll, dlbcl, follicular lymphoma, head and neck cancer, malignancy, mantle cell lymphoma, multiple myeloma, non-hodgkin lymphoma, ovarian cancer, pancreatic cancer, small cell lung cancer, soft tissue sarcoma, squamous cell carcinoma of head and neck, triple negative breast cancer